A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
AbbVie
AbbVie
Amgen
AbbVie
Sanofi
Pfizer
Anaveon AG
AbbVie
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Emory University
Sunnybrook Health Sciences Centre
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.